高级搜索
许雯雯, 朱宇熹. 第三代TKIs在EGFR突变非小细胞肺癌中的应用[J]. 肿瘤防治研究, 2021, 48(12): 1129-1134. DOI: 10.3971/j.issn.1000-8578.2021.21.0761
引用本文: 许雯雯, 朱宇熹. 第三代TKIs在EGFR突变非小细胞肺癌中的应用[J]. 肿瘤防治研究, 2021, 48(12): 1129-1134. DOI: 10.3971/j.issn.1000-8578.2021.21.0761
XU Wenwen, ZHU Yuxi. Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1129-1134. DOI: 10.3971/j.issn.1000-8578.2021.21.0761
Citation: XU Wenwen, ZHU Yuxi. Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1129-1134. DOI: 10.3971/j.issn.1000-8578.2021.21.0761

第三代TKIs在EGFR突变非小细胞肺癌中的应用

Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer

  • 摘要: 肿瘤治疗的个体化带来了临床实践变革。近年来,表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)对EGFR阳性突变的非小细胞肺癌显示出良好的抗肿瘤活性。第三代EGFR-TKIs相对于一代EGFR-TKI,显著提高了EGFR突变晚期非小细胞肺癌治疗的有效率、无进展生存期及总生存期,且对脑转移病灶有良好的疗效,对可手术的EGFR突变非小细胞肺癌术后辅助治疗也体现了无病生存获益,在联合放疗应用于局部晚期及晚期寡转移EGFR突变非小细胞肺癌中优势明显。

     

    Abstract: The individualization of cancer treatment has brought about revolution in clinical practice. In recent years, EGFR-TKI has shown good anti-tumor activity in non-small cell lung cancer with EGFR positive mutation. Compared with the first-generation EGFR-TKI, the third-generation EGFR-TKI significantly increased the effective rate, progression-free survival and overall survival of advanced non-small cell lung cancer with EGFR mutation, especially the brain metastases. And the third-generation EGFR-TKI also showed the benefits of disease-free survival as the post-operative adjuvant therapy for operable EGFR-mutated non-small cell lung cancer. Moreover, the third-generation EGFR-TKI in combination with radiotherapy showed obvious advantages in the treatment of locally advanced and advanced oligometastatic EGFR-mutated non-small cell lung cancer.

     

/

返回文章
返回